Ann: Trading Halt, page-36

The first of three trading halts we've 'all been waiting for'........................and in 6 months or so the other two should be delivered.

"US psoriasis market is significantly larger than the combined market for acne and atopic dermatitis, and is expected to grow to more than US$21bn by 2024"......

A positive outcome here combined with the deeper level 'mechanism of action' data should seriously drive both short and long term interest and value here imo.

"For the first time, investigation of molecular pathways that CBD might modulate to produce a benefit in skin disease"...................this is the big part of this study imo.

These 'mechanistic' results are going to be a big deal I feel, not just from a 'did the phase one outcomes deliver perspective' but also from an 'IP' viewpoint. Consider also the 'kudos' for being the first to elucidate or describe in detail the novel mechanisms of action for CBD in dermatology..........and then think on the concurrent possibilities this might present in the biochemistry/biology/genetics of such............we could unlock a whole knew suite of opportunities and understanding with this knowledge.

This is a 'world first' in the CBD dermatology space as far a we've been told.............not only do BOT have a convincing lead on the rest in this sector it's the 'knowing' on a deeper level that is also half of winning this battle imo.

BOT should now 'understand' what makes 'CBD tick' for the first time in terms of psoriasis pathology. Undoubtedly this information will have very real implications for our understanding of various other dermatological conditions and their response to CBD based treatments. As such this can only enhance the potential BOT are attempting to unlock here imo.

I'm excited.....good fortune to all.